Stoke Therapeutics Inc. (STOK)
Summary
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
Stoke Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 293 | $3,387.16 | $8,630.99 | $5,243.83 | 154.81% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3,352 | $105,305.04 | $98,549.81 | -$6,755.23 | -6.41% |
 Farallon Capital Farallon Capital Management LLC | 9,000 | $285,660 | $265,140 | -$20,520 | -7.18% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 10,876 | $354,122.56 | $320,406.96 | -$33,715.6 | -9.52% |
| BG Bart Gancher Intech Investment Management LLC | 14,494 | $247,956.53 | $425,978.66 | $178,022.13 | 71.8% |
Stoke Therapeutics Inc. (STOK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Stoke Therapeutics Inc. ever had a stock split?
Stoke Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ian F. Smith CEO | NASDAQ (NGS) Exchange | 86150R107 CUSIP |
| US Country | 170 Employees | - Last Dividend | 6 Jun 2019 Last Split | 19 Jun 2019 IPO Date |
Overview
Stoke Therapeutics, Inc. is an innovative early-stage biopharmaceutical company based in Bedford, Massachusetts, dedicated to developing treatments that address the root causes of severe genetic diseases. Founded in 2014, originally as ASOthera Pharmaceuticals, Inc., the company underwent a name change to Stoke Therapeutics, Inc. in May 2016. With a focus on leveraging its proprietary technology, targeted augmentation of nuclear gene output (TANGO), Stoke Therapeutics is at the forefront of creating antisense oligonucleotides that strategically increase protein levels to counteract genetic deficiencies. The company's collaborative efforts, including a notable agreement with Acadia Pharmaceuticals Inc., emphasize its commitment to uncovering RNA-based medicines for central nervous system disorders and other severe genetic conditions.
Products and Services
- STK-002:
In the preclinical stage, STK-002 is Stoke Therapeutics' leading candidate targeting the treatment of autosomal dominant optic atrophy. Utilizing the company's TANGO platform, STK-002 represents an innovative approach to restoring crucial protein levels to potentially halt or reverse the progression of this genetic eye disease by specifically targeting and correcting the underlying genetic cause.
- STK-001:
Currently in phase I/II clinical trials, STK-001 is aiming to address Dravet syndrome, a severe form of epilepsy. By focusing on the precise genetic mutations that result in Dravet syndrome, STK-001 exemplifies Stoke Therapeutics' commitment to targeted genetic therapies, offering hope for a condition currently lacking in adequate treatments.
- RNA-based Medicines for Neurodevelopmental Diseases:
Under a collaboration with Acadia Pharmaceuticals Inc., Stoke Therapeutics is expanding its horizons into developing novel RNA-based medicines. These treatments are specifically designed to target severe and rare genetic neurodevelopmental diseases affecting the central nervous system. This endeavor underscores the company's broader commitment to addressing haploinsufficiency diseases—conditions where a single functional copy of a gene does not produce enough protein—by exploring the potential of RNA therapies to correct these genetic imbalances.
